209 related articles for article (PubMed ID: 1705237)
21. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response.
McKenzie SJ; Halsey JF
J Immunol; 1984 Oct; 133(4):1818-24. PubMed ID: 6470484
[TBL] [Abstract][Full Text] [Related]
22. Enhanced immunological tolerance against allograft rejection by oral administration of allogeneic antigen linked to cholera toxin B subunit.
Sun JB; Li BL; Czerkinsky C; Holmgren J
Clin Immunol; 2000 Nov; 97(2):130-9. PubMed ID: 11027453
[TBL] [Abstract][Full Text] [Related]
23. Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses.
Lian T; Bui T; Ho RJ
Vaccine; 1999 Nov; 18(7-8):604-11. PubMed ID: 10547418
[TBL] [Abstract][Full Text] [Related]
24. HMGB1 released from intestinal epithelia damaged by cholera toxin adjuvant contributes to activation of mucosal dendritic cells and induction of intestinal cytotoxic T lymphocytes and IgA.
Wakabayashi A; Shimizu M; Shinya E; Takahashi H
Cell Death Dis; 2018 May; 9(6):631. PubMed ID: 29795370
[TBL] [Abstract][Full Text] [Related]
25. Cholera toxin as a mucosal adjuvant: III. Antibody responses to nontarget dietary antigens are not increased.
Nedrud JG; Sigmund N
Reg Immunol; 1990-1991; 3(5):217-22. PubMed ID: 1966580
[TBL] [Abstract][Full Text] [Related]
26. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
Nyström-Asklin J; Adamsson J; Harandi AM
Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.
Boberg A; Gaunitz S; Bråve A; Wahren B; Carlin N
Vaccine; 2008 Sep; 26(40):5079-82. PubMed ID: 18514370
[TBL] [Abstract][Full Text] [Related]
28. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.
Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H
Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of a food plant-based oral cholera toxin B subunit vaccine.
Arakawa T; Chong DK; Langridge WH
Nat Biotechnol; 1998 Mar; 16(3):292-7. PubMed ID: 9528012
[TBL] [Abstract][Full Text] [Related]
30. Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice.
Huang CF; Wu TC; Chu YH; Hwang KS; Wang CC; Peng HJ
Scand J Immunol; 2008 Nov; 68(5):502-10. PubMed ID: 18822109
[TBL] [Abstract][Full Text] [Related]
31. Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response.
Li S; Zheng W; Kuolee R; Hirama T; Henry M; Makvandi-Nejad S; Fjällman T; Chen W; Zhang J
Mol Immunol; 2009 May; 46(8-9):1718-26. PubMed ID: 19269688
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin.
Luci C; Hervouet C; Rousseau D; Holmgren J; Czerkinsky C; Anjuère F
J Immunol; 2006 Mar; 176(5):2749-57. PubMed ID: 16493030
[TBL] [Abstract][Full Text] [Related]
33. Enhanced soluble production of cholera toxin B subunit in Escherichia coli by co-expression of SKP chaperones.
Zhang Y; Qiao X; Yu X; Chen J; Hou L; Bi Z; Zheng Q; Hou J
Protein Expr Purif; 2017 Oct; 138():1-6. PubMed ID: 28673733
[TBL] [Abstract][Full Text] [Related]
34. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.
Wiedermann U; Jahn-Schmid B; Lindblad M; Rask C; Holmgren J; Kraft D; Ebner C
Int Immunol; 1999 Jul; 11(7):1131-8. PubMed ID: 10383946
[TBL] [Abstract][Full Text] [Related]
35. Direct interaction between cholera toxin and dendritic cells is required for oral adjuvant activity.
Gustafsson T; Hua YJ; Dahlgren MW; Livingston M; Johansson-Lindbom B; Yrlid U
Eur J Immunol; 2013 Jul; 43(7):1779-88. PubMed ID: 23649516
[TBL] [Abstract][Full Text] [Related]
36. Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice.
Rask C; Holmgren J; Fredriksson M; Lindblad M; Nordström I; Sun JB; Czerkinsky C
Clin Exp Allergy; 2000 Jul; 30(7):1024-32. PubMed ID: 10848926
[TBL] [Abstract][Full Text] [Related]
37. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.
Lycke N; Holmgren J
Immunology; 1986 Oct; 59(2):301-8. PubMed ID: 3021614
[TBL] [Abstract][Full Text] [Related]
38. Immune responses of mice to orally administered asialo GM1-specific rabbit IgG in the presence or absence of cholera toxin.
Umesaki Y; Setoyama H
Immunology; 1992 Feb; 75(2):386-8. PubMed ID: 1551702
[TBL] [Abstract][Full Text] [Related]
39. Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin.
Tamura S; Shoji Y; Hasiguchi K; Aizawa C; Kurata T
Vaccine; 1994 Oct; 12(13):1238-40. PubMed ID: 7839730
[TBL] [Abstract][Full Text] [Related]
40. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization.
Vajdy M; Lycke NY
Immunology; 1992 Mar; 75(3):488-92. PubMed ID: 1572696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
